1
|
Nakagiri T, Amatya VJ, Kushitani K, Kambara T, Aoe K, Endo I, Miyata Y, Okada M, Takeshima Y. Reply to "Correspondence: SPARC, HEG1, and the Diagnosis of Epithelioid Mesothelioma" by Churg et al. Am J Surg Pathol 2024; 48:632-634. [PMID: 38357938 DOI: 10.1097/pas.0000000000002190] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/16/2024]
Affiliation(s)
- Tetsuya Nakagiri
- Department of Pathology, Graduate School of Biomedical and Health Sciences, Hiroshima University Hiroshima, Japan
| | - Vishwa J Amatya
- Department of Pathology, Graduate School of Biomedical and Health Sciences, Hiroshima University Hiroshima, Japan
| | - Kei Kushitani
- Department of Pathology, Graduate School of Biomedical and Health Sciences, Hiroshima University Hiroshima, Japan
| | - Takahiro Kambara
- Department of Pathology, Graduate School of Biomedical and Health Sciences, Hiroshima University Hiroshima, Japan
| | - Kohei Aoe
- Department of Pathology, Graduate School of Biomedical and Health Sciences, Hiroshima University Hiroshima, Japan
| | - Ihiro Endo
- Department of Pathology, Graduate School of Biomedical and Health Sciences, Hiroshima University Hiroshima, Japan
| | - Yoshihiro Miyata
- Department of Surgical Oncology Research Institute for Radiation Biology and Medicine, Hiroshima University Hiroshima, Japan
| | - Morihito Okada
- Department of Surgical Oncology Research Institute for Radiation Biology and Medicine, Hiroshima University Hiroshima, Japan
| | - Yukio Takeshima
- Department of Pathology, Graduate School of Biomedical and Health Sciences, Hiroshima University Hiroshima, Japan
| |
Collapse
|
2
|
Nakagiri T, Amatya VJ, Kushitani K, Kambara T, Aoe K, Endo I, Miyata Y, Okada M, Takeshima Y. SPARC Is a Novel Positive Immunohistochemical Marker of Epithelioid Mesothelioma to Differentiate It From Lung Adenocarcinoma and/or Squamous Cell Carcinoma. Am J Surg Pathol 2024; 48:140-149. [PMID: 37899530 DOI: 10.1097/pas.0000000000002147] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2023]
Abstract
Epithelioid mesothelioma with a solid histologic pattern (solid epithelioid mesothelioma) is difficult to distinguish from a poorly differentiated squamous cell lung carcinoma and/or solid lung adenocarcinoma. Thus, immunohistochemical markers are essential for diagnosis; however, the sensitivity and specificity of pre-existing mesothelial markers are suboptimal, particularly for differentiation from squamous cell carcinoma. Using a cancer-dependency map, we analyzed gene expression data of pleural mesothelioma and non-small cell lung cancer cell lines (squamous cell carcinoma and adenocarcinoma) and identified secreted protein acidic and cysteine-rich (SPARC) as a promising candidate for the differential diagnosis of epithelioid mesothelioma from lung squamous cell carcinoma and/or lung adenocarcinoma. SPARC expression in mesothelioma and lung cancer cell lines was validated using reverse-transcription polymerase chain reaction, western blotting, and immunohistochemistry. Immunohistochemical staining was performed using anti-SPARC antibodies against solid epithelioid mesothelioma, solid lung adenocarcinoma, and poorly differentiated lung squamous cell carcinoma. SPARC positivity was seen in 42/45 (93.3%) of solid epithelioid mesothelioma, 2/40 (5%) solid lung adenocarcinoma, and 2/45 (4.5%) of lung squamous cell carcinomas. The sensitivity, specificity, and diagnostic accuracy for differentiating solid epithelioid mesothelioma from lung cancer (solid lung adenocarcinoma and poorly differentiated lung squamous cell carcinoma) were 93.3, 95.2, and 94.6%, respectively. In conclusion, SPARC is a novel mesothelial marker that can be used to differentiate epithelioid mesothelioma from squamous cell carcinoma and lung adenocarcinoma.
Collapse
Affiliation(s)
- Tetsuya Nakagiri
- Department of Pathology, Graduate School of Biomedical and Health Sciences
| | - Vishwa J Amatya
- Department of Pathology, Graduate School of Biomedical and Health Sciences
| | - Kei Kushitani
- Department of Pathology, Graduate School of Biomedical and Health Sciences
| | - Takahiro Kambara
- Department of Pathology, Graduate School of Biomedical and Health Sciences
| | - Kohei Aoe
- Department of Pathology, Graduate School of Biomedical and Health Sciences
| | - Ihiro Endo
- Department of Pathology, Graduate School of Biomedical and Health Sciences
| | - Yoshihiro Miyata
- Department of Surgical Oncology, Research Center for Radiation Casualty Medicine, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
| | - Morihito Okada
- Department of Surgical Oncology, Research Center for Radiation Casualty Medicine, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
| | - Yukio Takeshima
- Department of Pathology, Graduate School of Biomedical and Health Sciences
| |
Collapse
|
3
|
Aoe K, Orita Y, Oshita C, Date S, Teragawa H. Fatal myocardial infarction investigated using contrast-enhanced postmortem computed tomography: A case report. Clin Case Rep 2023; 11:e8340. [PMID: 38116516 PMCID: PMC10728368 DOI: 10.1002/ccr3.8340] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2023] [Revised: 11/27/2023] [Accepted: 12/07/2023] [Indexed: 12/21/2023] Open
Abstract
Conventional autopsies are considered standard methods for clarifying cause of death. However, because of the increasing use of computed tomography, magnetic resonance imaging, and other diagnostic imaging techniques, autopsy imaging is now more frequently adopted to identify diseases with unknown causes and sudden deaths. A 84-year-old man was diagnosed with acute myocardial infarction using coronary angiography. After taking oral antiplatelet medication in the catheterization laboratory, the patient suddenly coughed violently, lost consciousness, and was diagnosed with cardiac arrest. Spontaneous circulation did not return after 50 min of cardiopulmonary resuscitation. To elucidate the cause of the cardiac arrest, we performed contrast-enhanced postmortem computed tomography (PMCT), which revealed cardiac tamponade due to cardiac rupture of the inferior myocardium. Our findings reaffirm the effectiveness of contrast-enhanced PMCT in the diagnosis of sudden death in the clinical setting.
Collapse
Affiliation(s)
- Kohei Aoe
- Department of Clinical EducationJR Hiroshima HospitalHiroshimaJapan
| | - Yuichi Orita
- Department of Cardiovascular MedicineJR Hiroshima HospitalHiroshimaJapan
| | - Chikage Oshita
- Department of Cardiovascular MedicineJR Hiroshima HospitalHiroshimaJapan
| | - Shuji Date
- Department of RadiologyJR Hiroshima HospitalHiroshimaJapan
| | - Hiroki Teragawa
- Department of Cardiovascular MedicineJR Hiroshima HospitalHiroshimaJapan
| |
Collapse
|
4
|
Endo I, Amatya VJ, Kushitani K, Nakagiri T, Aoe K, Takeshima Y. Long Non-coding RNA LINC00152 Requires EZH2 to Promote Mesothelioma Cell Proliferation, Migration, and Invasion. Anticancer Res 2023; 43:5367-5376. [PMID: 38030172 DOI: 10.21873/anticanres.16740] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2023] [Revised: 11/13/2023] [Accepted: 11/14/2023] [Indexed: 12/01/2023]
Abstract
BACKGROUND/AIM Long non-coding RNAs (lncRNAs) establish gene regulatory networks in different human cancers and are involved in tumorigenesis. lncRNA LINC00152 is over-expressed in several malignant tumors and involved in tumorigenesis; however, its underlying regulatory mechanisms remain unclear. Mesothelioma, a cancer originating from mesothelial cells, is highly aggressive with a poor prognosis. Therefore, identification of new therapeutic targets is necessary for mesothelioma treatment. MATERIALS AND METHODS Here, we conducted bioinformatics analyses of LINC00152 and enhancer of zeste homolog 2 (EZH2) expression levels and their correlation with the prognosis of patients with mesothelioma. Small interfering RNAs targeting LINC00152 and EZH2 were transfected into mesothelioma cell lines to analyze their biological functions and regulatory mechanisms. RESULTS High LINC00152 expression was associated with a poor prognosis of patients with mesothelioma. LINC00152 knockdown inhibited the proliferation, migration, and invasion of mesothelioma cell lines. These results suggest that LINC00152 is a tumor-promoting factor in mesothelioma. EZH2 is highly expressed in mesothelioma and other malignancies. Direct interaction between LINC00152 and EZH2 is associated with cancer development and progression. When EZH2 expression was suppressed, LINC00152 knockdown did not suppress the proliferation, migration, and invasion of mesothelioma cells. Therefore, the tumor-promoting effect of LINC00152 in mesothelioma was dependent on EZH2 expression. CONCLUSION LINC00152 promotes mesothelioma cell proliferation, migration, and invasion in cooperation with EZH2, highlighting its potential as an effective therapeutic target for mesothelioma.
Collapse
Affiliation(s)
- Ihiro Endo
- Department of Pathology, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan
| | - Vishwa Jeet Amatya
- Department of Pathology, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan
| | - Kei Kushitani
- Department of Pathology, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan
| | - Tetsuya Nakagiri
- Department of Pathology, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan
| | - Kohei Aoe
- Department of Pathology, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan
| | - Yukio Takeshima
- Department of Pathology, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan
| |
Collapse
|
5
|
Endo I, Amatya VJ, Kushitani K, Kambara T, Nakagiri T, Aoe K, Takeshima Y. FOXM1 Promotes Mesothelioma Cell Migration and Invasion via Activation of SMAD Signaling. Anticancer Res 2023; 43:3961-3968. [PMID: 37648326 DOI: 10.21873/anticanres.16583] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2023] [Revised: 07/04/2023] [Accepted: 07/05/2023] [Indexed: 09/01/2023]
Abstract
BACKGROUND/AIM Forkhead box M1 (FOXM1) is a transcription factor closely associated with various human malignancies and is considered an attractive target for cancer therapy. Mesothelioma is a malignancy primarily due to asbestos exposure and certain genetic factors, requiring a better understanding of tumorigenesis for improved treatment. Asbestos-exposed human mesothelial cells have been reported to up-regulate FOXM1 expression in a dose-dependent manner. MATERIALS AND METHODS FOXM1 expression was evaluated in mesothelioma tissues and cell lines. FOXM1 small interfering RNA was transfected into mesothelioma cell lines to analyze its biological functions and regulatory mechanisms. RESULTS FOXM1 was over-expressed in mesothelioma tissues and cell lines. Knock-down of FOXM1 in mesothelioma cell lines inhibited cell proliferation, migration, and invasion. These results suggest that up-regulation of FOXM1 expression promotes mesothelioma tumorigenesis and progression. We previously reported that insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3) promotes the proliferation, migration, and invasion of mesothelioma cell lines. In this study, IGF2BP3 knock-down suppressed FOXM1 expression in mesothelioma cell lines. Our results suggest that IGF2BP3, an upstream regulator, contributes to increased FOXM1 expression. Furthermore, IGF2BP3 and FOXM1 knock-down suppressed SMAD signaling by inhibiting SMAD2/3 phosphorylation in mesothelioma cell lines. CONCLUSION IGF2BP3/FOXM1 promotes mesothelioma cell migration and invasion via SMAD signaling, highlighting IGF2BP3/FOXM1 as a potential target for mesothelioma treatment.
Collapse
Affiliation(s)
- Ihiro Endo
- Department of Pathology, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan
| | - Vishwa Jeet Amatya
- Department of Pathology, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan
| | - Kei Kushitani
- Department of Pathology, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan
| | - Takahiro Kambara
- Department of Pathology, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan
| | - Tetsuya Nakagiri
- Department of Pathology, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan
| | - Kohei Aoe
- Department of Pathology, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan
| | - Yukio Takeshima
- Department of Pathology, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan
| |
Collapse
|
6
|
Endo I, Amatya VJ, Kushitani K, Nakagiri T, Aoe K, Takeshima Y. miR-142-3p Suppresses Invasion and Adhesion of Mesothelioma Cells by Downregulating ITGAV. Pathobiology 2023; 90:270-280. [PMID: 36724751 DOI: 10.1159/000528670] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2022] [Accepted: 12/12/2022] [Indexed: 02/03/2023] Open
Abstract
INTRODUCTION Malignant mesothelioma is an aggressive cancer associated with asbestos exposure. Currently, the efficacy of therapeutics is limited in malignant mesothelioma, and developing more effective therapies is the need of the hour. Non-coding RNAs (ncRNAs), including microRNAs (miRNAs), have attracted attention as therapeutic targets. To explore potential therapeutic targets, we focused on miR-142-3p expression, which was found to be significantly downregulated in mesothelioma cell lines in our previous study. METHODS Mesothelioma cell lines and tissues were validated for expression of miR-142-3p or integrin subunit alpha-V (ITGAV). We transfected mesothelioma cell lines with miR-142-3p mimic and ITGAV siRNA and analyzed their biological functions. RESULTS We found that miR-142-3p was significantly downregulated in mesothelioma tissues. Transfection with miR-142-3p mimic significantly suppressed cell proliferation, migration, and invasion. Bioinformatics analysis of potential targets of miR-142-3p identified ITGAV. Membrane ITGAV expression in mesothelioma cell lines was confirmed using immunocytochemistry. ITGAV was significantly upregulated in mesothelioma tissues. Moreover, transfection of miR-142-3p mimics into mesothelioma cell lines significantly suppressed ITGAV expression, indicating that miR-142-3p targets ITGAV. Next, ITGAV siRNA transfection into mesothelioma cell lines inhibited cell proliferation, migration, and invasion. Further investigation of cell adhesion mechanisms showed that the miR-142-3p/ITGAV axis specifically affects mesothelioma cell adhesion via vitronectin in the extracellular matrix. CONCLUSION This study proposed that the miR-142-3p/ITGAV axis is involved in tumor progression in malignant mesothelioma.
Collapse
Affiliation(s)
- Ihiro Endo
- Department of Pathology, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan,
| | - Vishwa Jeet Amatya
- Department of Pathology, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan
| | - Kei Kushitani
- Department of Pathology, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan
| | - Tetsuya Nakagiri
- Department of Pathology, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan
| | - Kohei Aoe
- Department of Pathology, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan
| | - Yukio Takeshima
- Department of Pathology, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan
| |
Collapse
|
7
|
Hayashi H, Okada M, Kijima T, Aoe K, Kato T, Fujimoto N, Nakagawa K, Takeda Y, Hida T, Kanai K, Hirano J, Namba Y, Ohe Y. 1895MO Three-year follow-up results of the MERIT trial: A Japanese phase II study of nivolumab in malignant pleural mesothelioma. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1438] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
8
|
Fujimoto N, Kozuki T, Aoe K, Miyamoto Y, Wada S, Harada D, Yoshida M, Sakurai J, Hotta K. 1898P A phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma: JME-001. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1441] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
9
|
Ninomiya T, Nogami N, Kozuki T, Harada D, Kubo T, Ohashi K, Kuyama S, Kudo K, Bessho A, Fujimoto N, Aoe K, Shibayama T, Minami D, Sugimoto K, Ochi N, Takigawa N, Hotta K, Kiura K. Updated analysis of a phase I trial of afatinib (Afa) and bevacizumab (Bev) in chemo-naïve patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring EGFR-mutations: OLCSG1404. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz260.047] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
10
|
Nakano T, Okada M, Kijima T, Aoe K, Kato T, Fujimoto N, Nakagawa K, Takeda Y, Hida T, Kanai K, Imamura F, Oizumi S, Takahashi T, Takenoyama M, Tanaka H, Ohe Y. OA08.01 Long-Term Efficacy and Safety of Nivolumab in Second- or Third-Line Japanese Malignant Pleural Mesothelioma Patients (Phase II: MERIT Study). J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.275] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
11
|
Harada D, Kozuki T, Nogami N, Hotta K, Aoe K, Ohashi K, Ninomiya K, Hirata T, Hinotsu S, Toyooka S, Kiura K. MA 07.11 A Phase II Study of Trastuzumab Emtansine in HER2-positive Non-Small-Cell-Lung Cancer. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.511] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
12
|
Goto Y, Okada M, Kijima T, Aoe K, Kato T, Fujimoto N, Nakagawa K, Takeda Y, Hida T, Kanai K, Imamura F, Oizumi S, Takahashi T, Takenoyama M, Tanaka H, Ohe Y. MA 19.01 A Phase II Study of Nivolumab: A Multicenter, Open-Label, Single Arm Study in Malignant Pleural Mesothelioma (MERIT). J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.634] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
13
|
Harada D, Nogami N, Kozuki T, Ninomiya T, Bessho A, Kuyama S, Fujimoto N, Sugimoto K, Aoe K, Ochi N, Minami D, Fukamatsu N, Kudo K, Kiura K. A phase I trial of afatinib (Afa) and bevacizumab (Bev) in chemo-naïve patients (pts) with advanced non-small-cell lung cancer (NSCLC) harboring EGFR-mutations: OLCSG1404. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx671.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
14
|
Tanaka T, Yoshioka H, Bessho A, Ishikawa N, Yamasaki M, Shibayama T, Aoe K, Kozuki T, Fujimoto N, Genba K, Ueda Y, Inoue M, Murakami T, Kuyama S, Kawai H, Fujitaka K, Inoue K, Takata M, Yanai H, Kiura K. A large prospective cohort study of the clinical features of advanced lung cancer harboring HER2 aberrations (HER2-CS STUDY). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx380.041] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
15
|
Oze I, Nagamatsu Y, Aoe K, Hotta K, Kato K, Nakagawa J, Hara K, Kishimoto T, Fujimoto N. Evaluation of quality of life in survivors with malignant pleural mesothelioma in Japan. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx389.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
16
|
Murata Y, Aoe K, Mimura-Kimura Y, Murakami T, Oishi K, Matsumoto T, Ueoka H, Matsunaga K, Yano M, Mimura Y. Association of immunoglobulin G4 and free light chain with idiopathic pleural effusion. Clin Exp Immunol 2017; 190:133-142. [PMID: 28617941 DOI: 10.1111/cei.12999] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/13/2017] [Indexed: 12/24/2022] Open
Abstract
The cause of pleural effusion remains uncertain in approximately 15% of patients despite exhaustive evaluation. As recently described immunoglobulin (Ig)G4-related disease is a fibroinflammatory disorder that can affect various organs, including the lungs, we investigate whether idiopathic pleural effusion includes IgG4-associated etiology. Between 2000 and 2012, we collected 830 pleural fluid samples and reviewed 35 patients with pleural effusions undiagnosed after pleural biopsy at Yamaguchi-Ube Medical Center. Importantly, IgG4 immunostaining revealed infiltration of IgG4-positive plasma cells in the pleura of 12 patients (34%, IgG4+ group). The median effusion IgG4 level was 41 mg/dl in the IgG4+ group and 27 mg/dl in the IgG4- group (P < 0·01). The light and heavy chains of effusion IgG4 antibodies of patients in the IgG4+ group were heterogeneous by two-dimensional electrophoresis, indicating the absence of clonality of the IgG4 antibodies. Interestingly, the κ light chains were more heterogeneous than the λ light chains. The measurement of the κ and λ free light chain (FLC) levels in the pleural fluids showed significantly different κ FLC levels (median: 28·0 versus 9·1 mg/dl, P < 0·01) and κ/λ ratios (median: 2·0 versus 1·2, P < 0·001) between the IgG4+ and IgG4- groups. Furthermore, the κ/λ ratios were correlated with the IgG4+ /IgG+ plasma cell ratios in the pleura of the IgG4+ group. Taken together, these results demonstrate the involvement of IgG4 in certain idiopathic pleural effusions and provide insights into the diagnosis, pathogenesis and therapeutic opportunities of IgG4-associated pleural effusion.
Collapse
Affiliation(s)
- Y Murata
- The Department of Clinical Research, National Hospital Organization Yamaguchi-Ube Medical Center, Ube, Japan.,The Department of Respiratory Medicine, National Hospital Organization Yamaguchi-Ube Medical Center, Ube, Japan.,Division of Cardiology, The Department of Medicine and Clinical Science, Ube, Japan
| | - K Aoe
- The Department of Clinical Research, National Hospital Organization Yamaguchi-Ube Medical Center, Ube, Japan
| | - Y Mimura-Kimura
- The Department of Clinical Research, National Hospital Organization Yamaguchi-Ube Medical Center, Ube, Japan
| | - T Murakami
- The Department of Clinical Research, National Hospital Organization Yamaguchi-Ube Medical Center, Ube, Japan
| | - K Oishi
- The Department of Clinical Research, National Hospital Organization Yamaguchi-Ube Medical Center, Ube, Japan.,The Department of Respiratory Medicine, National Hospital Organization Yamaguchi-Ube Medical Center, Ube, Japan.,Division of Cardiology, The Department of Medicine and Clinical Science, Ube, Japan
| | - T Matsumoto
- The Department of Clinical Research, National Hospital Organization Yamaguchi-Ube Medical Center, Ube, Japan
| | - H Ueoka
- The Department of Clinical Research, National Hospital Organization Yamaguchi-Ube Medical Center, Ube, Japan
| | - K Matsunaga
- The Department of Respiratory Medicine and Infectious Disease, Yamaguchi University Graduate School of Medicine, Ube, Japan
| | - M Yano
- Division of Cardiology, The Department of Medicine and Clinical Science, Ube, Japan
| | - Y Mimura
- The Department of Clinical Research, National Hospital Organization Yamaguchi-Ube Medical Center, Ube, Japan
| |
Collapse
|
17
|
Urata Y, Sueoka-Aragane N, Katakami N, Satouchi M, Yokota S, Aoe K, Iwanaga K, Otsuka K, Kimura S, Negoro S. Monitoring Egfr T790M Using Plasma Dna in Lung Cancer Patients Treated with Egfr Tyrosine Kinase Inhibitor in a Prospective Observational Study. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu349.48] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
18
|
Nogami N, Ichihara E, Kozuki T, Kubo T, Kishino D, Kuyama S, Bessho A, Fujii M, Takigawa N, Chikamori K, Aoe K, Nagata T, Fujimoto N, Hosokawa S, Harita S, Kamei H, Ueoka H, Hotta K, Tanimoto M, Kiura K. A Phase Ii Trial of Gefitinib in Combination with Bevacizumab As First-Line Therapy for Advanced Non-Small-Cell Lung Cancer with Activating Egfr Gene Mutations: Olcsg 1001. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu349.64] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
19
|
Yamamoto J, Ohnuma K, Hatano R, Okamoto T, Komiya E, Yamazaki H, Iwata S, Dang NH, Aoe K, Kishimoto T, Yamada T, Morimoto C. Regulation of somatostatin receptor 4-mediated cytostatic effects by CD26 in malignant pleural mesothelioma. Br J Cancer 2014; 110:2232-45. [PMID: 24743707 PMCID: PMC4007235 DOI: 10.1038/bjc.2014.151] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2014] [Accepted: 02/26/2014] [Indexed: 02/07/2023] Open
Abstract
Background: Malignant pleural mesothelioma (MPM) is an aggressive neoplasm arising from mesothelial lining of pleura. CD26 molecules preferentially expressed on epithelioid type of MPM. This study investigates the molecular mechanisms of CD26 regulating MPM cells in vitro and in vivo. Methods: Biochemical and cell biological approaches were used for identifying a novel molecular target of MPM. Its contribution to tumour expansion has been also assessed using animal models. The clinical samples of MPM were also assessed for its expression. Results: We identify that cytostatic effects in MPM are mediated by somatostatin (SST) receptor 4 (SSTR4), being inhibited by the interaction of CD26 molecules. We also indicates that SSTR4-mediated cytostatic effects are regulated by SHP-2 PTP, and that this inhibitory effect by SST agonist is enhanced via lipid raft clustering of associated molecules following crosslinking of anti-CD26 antibody. Finally, using an in vivo xenograft model, we demonstrate that the anti-tumour effect of anti-CD26 mAb is enhanced when combined with SSTR4 agonist treatment, and that SSTR4 is highly coexpressed with CD26 on epithelioid or biphasic types of MPM tissues obtained from patients' surgical specimens. Conclusions: Combination therapy with humanised anti-CD26 mAb and SSTR4 agonist may therefore potentiate anti-tumour effect on MPM.
Collapse
Affiliation(s)
- J Yamamoto
- Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, 2-1-1, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan
| | - K Ohnuma
- Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, 2-1-1, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan
| | - R Hatano
- Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, 2-1-1, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan
| | - T Okamoto
- Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, 2-1-1, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan
| | - E Komiya
- Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, 2-1-1, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan
| | - H Yamazaki
- Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, 2-1-1, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan
| | - S Iwata
- Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, 2-1-1, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan
| | - N H Dang
- Division of Hematology/Oncology, University of Florida, 1600 SW Archer Road, Box 100278, Room MSB M410A, Gainesville, FL 32610, USA
| | - K Aoe
- Department of Medical Oncology and Clinical Research, National Hospital Organization Yamaguchi-Ube Medical Center, 685 Higashi-Kiwa, Ube, Yamaguchi 755-0241, Japan
| | - T Kishimoto
- Department of Respiratory Medicine, Okayama Rosai Hospital, 1-10-25 Chikkomidorimachi, Okayama Minami-ku, Okayama 702-8055, Japan
| | - T Yamada
- Department of Pathology, Keio University School of Medicine, 35 Shinanomachi Shinjuku-ku, Tokyo 160-8582, Japan
| | - C Morimoto
- Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, 2-1-1, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan
| |
Collapse
|
20
|
Aoe K, Hiraki A, Fujimoto N, Gemba K, Kishimoto T. The first nationwide survival analysis of Japanese mesothelioma patients from Vital Statistics of Japan. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e12007] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
21
|
Kuyama S, Segawa Y, Nogami N, Kiura K, Takigawa N, Shibayama T, Hosokawa S, Aoe K, Tabata M, Tanimoto M. A phase II trial of combination chemotherapy with irinotecan and amrubicin in pretreated patients with non-small cell lung cancer (NSCLC): Results of Okayama Lung Cancer Study Group Trial 0402. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e19029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e19029 Background: We previously conducted a phase I trial of combination chemotherapy with irinotecan and amrubicin for NSCLC and found acceptable toxicity profiles with a favorable efficacy in patients with pretreated NSCLC. The aim of this phase II trial was to further evaluate its efficacy and toxicity in this population with a long-term follow-up. Methods: Primary endpoint was objective response. Patients with NSCLC previously treated with one or two chemotherapy regimens were enrolled in this trial. Irinotecan and amrubicin were both administered on days 1 and 8, every 3 weeks at doses of 100 and 40 mg/m2, respectively. Response and toxicity were assessed according to the RECIST guideline and NCI-CTC for AE v3.0. Results: Thirty-one pretreated NSCLC patients were enrolled between 2004 and 2006. A median number of courses administered was 3 (range: 1 to 6). All patients and courses were assessable for efficacy and safety. Demographics of the patients were as follows: M/F:21/10, Ad/others:21/10, ECOG-PS 0/1:12/19, and smoker/non-smoker:21/10. Platinum-based regimens were commonly used as the prior chemotherapy. Objective response was obtained in 9 of the 31 patients with a response rate of 29.0% (95%CI: 12.1–46.0%). Grade 4 leukopenia and neutropenia were observed in 6 (19%) and 14 (45%) patients, respectively, whereas thrombocytopenia were generally mild. Grade 3 febrile neutropenia was observed in 7 patients (23%), of whom two patients further developed Grade 4 and 5 septic shock each. Other grade 3 or greater non-hematological toxicities included diarrhea, vomiting, pneumonitis, liver dysfunction in 4, 1, 1 and 2 patients, respectively. With a median follow-up time of 24.2 months, median survival time and median progression-free survival time were 14.2 and 4.0 months, respectively. Conclusions: This combination seemed highly effective for pretreated NSCLC with an acceptable toxicity. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- S. Kuyama
- Chugoku Central Hospital, Fukuyama, Japan; NHO Shikoku Cancer Center, Matsuyama, Japan; Okayama University Hospital, Okayama, Japan; NHO Minami-Okayama Medical Center, Okayama, Japan; Okayama Red Cross Hospital, Okayama, Japan; NHO Yamaguchi Ube Medical Center, Ube, Japan
| | - Y. Segawa
- Chugoku Central Hospital, Fukuyama, Japan; NHO Shikoku Cancer Center, Matsuyama, Japan; Okayama University Hospital, Okayama, Japan; NHO Minami-Okayama Medical Center, Okayama, Japan; Okayama Red Cross Hospital, Okayama, Japan; NHO Yamaguchi Ube Medical Center, Ube, Japan
| | - N. Nogami
- Chugoku Central Hospital, Fukuyama, Japan; NHO Shikoku Cancer Center, Matsuyama, Japan; Okayama University Hospital, Okayama, Japan; NHO Minami-Okayama Medical Center, Okayama, Japan; Okayama Red Cross Hospital, Okayama, Japan; NHO Yamaguchi Ube Medical Center, Ube, Japan
| | - K. Kiura
- Chugoku Central Hospital, Fukuyama, Japan; NHO Shikoku Cancer Center, Matsuyama, Japan; Okayama University Hospital, Okayama, Japan; NHO Minami-Okayama Medical Center, Okayama, Japan; Okayama Red Cross Hospital, Okayama, Japan; NHO Yamaguchi Ube Medical Center, Ube, Japan
| | - N. Takigawa
- Chugoku Central Hospital, Fukuyama, Japan; NHO Shikoku Cancer Center, Matsuyama, Japan; Okayama University Hospital, Okayama, Japan; NHO Minami-Okayama Medical Center, Okayama, Japan; Okayama Red Cross Hospital, Okayama, Japan; NHO Yamaguchi Ube Medical Center, Ube, Japan
| | - T. Shibayama
- Chugoku Central Hospital, Fukuyama, Japan; NHO Shikoku Cancer Center, Matsuyama, Japan; Okayama University Hospital, Okayama, Japan; NHO Minami-Okayama Medical Center, Okayama, Japan; Okayama Red Cross Hospital, Okayama, Japan; NHO Yamaguchi Ube Medical Center, Ube, Japan
| | - S. Hosokawa
- Chugoku Central Hospital, Fukuyama, Japan; NHO Shikoku Cancer Center, Matsuyama, Japan; Okayama University Hospital, Okayama, Japan; NHO Minami-Okayama Medical Center, Okayama, Japan; Okayama Red Cross Hospital, Okayama, Japan; NHO Yamaguchi Ube Medical Center, Ube, Japan
| | - K. Aoe
- Chugoku Central Hospital, Fukuyama, Japan; NHO Shikoku Cancer Center, Matsuyama, Japan; Okayama University Hospital, Okayama, Japan; NHO Minami-Okayama Medical Center, Okayama, Japan; Okayama Red Cross Hospital, Okayama, Japan; NHO Yamaguchi Ube Medical Center, Ube, Japan
| | - M. Tabata
- Chugoku Central Hospital, Fukuyama, Japan; NHO Shikoku Cancer Center, Matsuyama, Japan; Okayama University Hospital, Okayama, Japan; NHO Minami-Okayama Medical Center, Okayama, Japan; Okayama Red Cross Hospital, Okayama, Japan; NHO Yamaguchi Ube Medical Center, Ube, Japan
| | - M. Tanimoto
- Chugoku Central Hospital, Fukuyama, Japan; NHO Shikoku Cancer Center, Matsuyama, Japan; Okayama University Hospital, Okayama, Japan; NHO Minami-Okayama Medical Center, Okayama, Japan; Okayama Red Cross Hospital, Okayama, Japan; NHO Yamaguchi Ube Medical Center, Ube, Japan
| | | |
Collapse
|
22
|
Kamei T, Okamura H, Sakuma N, Shibuta H, Aoe K, Murakami T. 240 Immunocytochemistry with ten commercially available antibodies in adenocarcinoma cells, malignant or reactive mesothelial cells in serous effusions. Lung Cancer 2006. [DOI: 10.1016/s0169-5002(07)70316-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
23
|
Hiraki A, Aoe K, Murakami T, Toyooka S, Shivapurkar N, Gazdar A, Sueoka N, Sugi K, Ueoka H, Kishimoto T. Evidence against a role for simian virus 40 in malignant mesothelioma in Japan. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.10040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
10040 Background: Malignant mesothelioma is a highly aggressive tumor arising from serosal membranes, most commonly the pleura. Worldwide incidence is increasing because of widespread exposure to asbestos, the major causal agent. Incidence of this disease also is increasing dramatically in Japan. Association of simian virus 40 (SV40) with malignant mesothelioma has been reported, suggesting that SV40 plays an important role in the origin of a subset of these tumors. Most recently, evidence against any role for SV40 in this disease has been also reported. The role of SV40 in malignant mesothelioma remains still controversial. In addition, it has been argued that differences in the reported frequency of SV40 detection in malignant mesothelioma may be related to geographic variation in populations exposed to the virus. Whether SV40 is associated with malignant mesothelioma in Japan therefore is an important issue. However, no study concerning SV40 in malignant mesothelioma has been reported from Japan. Methods: To address this, we studied 35 malignant mesotheliomas including 32 men and 3 women with a median age of 61 years (ranges 34 to 85) and examined the presence of SV40 large T antigen DNA with real time PCR based on TaqMan technology using primers that PCR amplified a specific 156-bp region of the large Tag of SV40 as well as its expression with immnohistological methods using anti-SV40 large T antigen antibody (pAb101, Santa Cruz Biotechnology, Inc., CA). Results: Two of 35 mesotheliomas were considered positive for the presence of SV40 large T antigen DNA, showing ratios of 36.0 and 4.9. The ratio in the positive control was 199.0. The two positive cases consisted of one epithelioid tumor and one biphasic tumor. In addition, none of 35 malignant mesothelioma specimens were positve for staining with SV40 large T antigen antibody; in contrast, diffuse staining for SV40 large T antigen was observed in the cytoplasm and on the cell membranes in the positive control. Conclusions: Taken together, these findings strongly argue against any role of SV40 in the etiology of the majority of malignant mesothelioma in Japan. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- A. Hiraki
- NHO Sanyo National Hospital, Ube, Japan; Okayama University, Okayama, Japan; University of Texas Southwestern Medical Center, Dallas, TX; Saga University, Saga, Japan; Okayama Rosai Hospital, Okayma, Japan
| | - K. Aoe
- NHO Sanyo National Hospital, Ube, Japan; Okayama University, Okayama, Japan; University of Texas Southwestern Medical Center, Dallas, TX; Saga University, Saga, Japan; Okayama Rosai Hospital, Okayma, Japan
| | - T. Murakami
- NHO Sanyo National Hospital, Ube, Japan; Okayama University, Okayama, Japan; University of Texas Southwestern Medical Center, Dallas, TX; Saga University, Saga, Japan; Okayama Rosai Hospital, Okayma, Japan
| | - S. Toyooka
- NHO Sanyo National Hospital, Ube, Japan; Okayama University, Okayama, Japan; University of Texas Southwestern Medical Center, Dallas, TX; Saga University, Saga, Japan; Okayama Rosai Hospital, Okayma, Japan
| | - N. Shivapurkar
- NHO Sanyo National Hospital, Ube, Japan; Okayama University, Okayama, Japan; University of Texas Southwestern Medical Center, Dallas, TX; Saga University, Saga, Japan; Okayama Rosai Hospital, Okayma, Japan
| | - A. Gazdar
- NHO Sanyo National Hospital, Ube, Japan; Okayama University, Okayama, Japan; University of Texas Southwestern Medical Center, Dallas, TX; Saga University, Saga, Japan; Okayama Rosai Hospital, Okayma, Japan
| | - N. Sueoka
- NHO Sanyo National Hospital, Ube, Japan; Okayama University, Okayama, Japan; University of Texas Southwestern Medical Center, Dallas, TX; Saga University, Saga, Japan; Okayama Rosai Hospital, Okayma, Japan
| | - K. Sugi
- NHO Sanyo National Hospital, Ube, Japan; Okayama University, Okayama, Japan; University of Texas Southwestern Medical Center, Dallas, TX; Saga University, Saga, Japan; Okayama Rosai Hospital, Okayma, Japan
| | - H. Ueoka
- NHO Sanyo National Hospital, Ube, Japan; Okayama University, Okayama, Japan; University of Texas Southwestern Medical Center, Dallas, TX; Saga University, Saga, Japan; Okayama Rosai Hospital, Okayma, Japan
| | - T. Kishimoto
- NHO Sanyo National Hospital, Ube, Japan; Okayama University, Okayama, Japan; University of Texas Southwestern Medical Center, Dallas, TX; Saga University, Saga, Japan; Okayama Rosai Hospital, Okayma, Japan
| |
Collapse
|
24
|
Katayama H, Aoe K, Hiraki A, Fujiwara K, Maeda T, Murakami T, Eda R, Sugi K, Takeyama H. Identification of epigenetic aberrant promoter methylation in pleural fluid DNA is useful for diagnosis of malignant pleural effusion. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.9567] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- H. Katayama
- National Hosp Organization Natl Sanyo Hosp, Ube, Japan; Univ of Texas Health Science Ctr, San Antonio, TX
| | - K. Aoe
- National Hosp Organization Natl Sanyo Hosp, Ube, Japan; Univ of Texas Health Science Ctr, San Antonio, TX
| | - A. Hiraki
- National Hosp Organization Natl Sanyo Hosp, Ube, Japan; Univ of Texas Health Science Ctr, San Antonio, TX
| | - K. Fujiwara
- National Hosp Organization Natl Sanyo Hosp, Ube, Japan; Univ of Texas Health Science Ctr, San Antonio, TX
| | - T. Maeda
- National Hosp Organization Natl Sanyo Hosp, Ube, Japan; Univ of Texas Health Science Ctr, San Antonio, TX
| | - T. Murakami
- National Hosp Organization Natl Sanyo Hosp, Ube, Japan; Univ of Texas Health Science Ctr, San Antonio, TX
| | - R. Eda
- National Hosp Organization Natl Sanyo Hosp, Ube, Japan; Univ of Texas Health Science Ctr, San Antonio, TX
| | - K. Sugi
- National Hosp Organization Natl Sanyo Hosp, Ube, Japan; Univ of Texas Health Science Ctr, San Antonio, TX
| | - H. Takeyama
- National Hosp Organization Natl Sanyo Hosp, Ube, Japan; Univ of Texas Health Science Ctr, San Antonio, TX
| |
Collapse
|
25
|
Hotta K, Harita S, Bessho A, Yonei T, Gemba K, Aoe K, Tabata M, Kiura K, Ueoka H, Tanimoto M. Interstitial lung disease (ILD) during gefitinib treatment in Japanese patients with non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.7063] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- K. Hotta
- Okayama University Medical School, Okayama, Japan; Chugoku Central Hospital, Fukuyama, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Japan; National Okayama Medical Center, Okayama, Japan; Okayama Rousai Hospital, Okayama, Japan; National Sanyo Hospital, Ube, Japan
| | - S. Harita
- Okayama University Medical School, Okayama, Japan; Chugoku Central Hospital, Fukuyama, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Japan; National Okayama Medical Center, Okayama, Japan; Okayama Rousai Hospital, Okayama, Japan; National Sanyo Hospital, Ube, Japan
| | - A. Bessho
- Okayama University Medical School, Okayama, Japan; Chugoku Central Hospital, Fukuyama, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Japan; National Okayama Medical Center, Okayama, Japan; Okayama Rousai Hospital, Okayama, Japan; National Sanyo Hospital, Ube, Japan
| | - T. Yonei
- Okayama University Medical School, Okayama, Japan; Chugoku Central Hospital, Fukuyama, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Japan; National Okayama Medical Center, Okayama, Japan; Okayama Rousai Hospital, Okayama, Japan; National Sanyo Hospital, Ube, Japan
| | - K. Gemba
- Okayama University Medical School, Okayama, Japan; Chugoku Central Hospital, Fukuyama, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Japan; National Okayama Medical Center, Okayama, Japan; Okayama Rousai Hospital, Okayama, Japan; National Sanyo Hospital, Ube, Japan
| | - K. Aoe
- Okayama University Medical School, Okayama, Japan; Chugoku Central Hospital, Fukuyama, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Japan; National Okayama Medical Center, Okayama, Japan; Okayama Rousai Hospital, Okayama, Japan; National Sanyo Hospital, Ube, Japan
| | - M. Tabata
- Okayama University Medical School, Okayama, Japan; Chugoku Central Hospital, Fukuyama, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Japan; National Okayama Medical Center, Okayama, Japan; Okayama Rousai Hospital, Okayama, Japan; National Sanyo Hospital, Ube, Japan
| | - K. Kiura
- Okayama University Medical School, Okayama, Japan; Chugoku Central Hospital, Fukuyama, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Japan; National Okayama Medical Center, Okayama, Japan; Okayama Rousai Hospital, Okayama, Japan; National Sanyo Hospital, Ube, Japan
| | - H. Ueoka
- Okayama University Medical School, Okayama, Japan; Chugoku Central Hospital, Fukuyama, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Japan; National Okayama Medical Center, Okayama, Japan; Okayama Rousai Hospital, Okayama, Japan; National Sanyo Hospital, Ube, Japan
| | - M. Tanimoto
- Okayama University Medical School, Okayama, Japan; Chugoku Central Hospital, Fukuyama, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Japan; National Okayama Medical Center, Okayama, Japan; Okayama Rousai Hospital, Okayama, Japan; National Sanyo Hospital, Ube, Japan
| |
Collapse
|
26
|
Hiraki A, Aoe K, Matsuo K, Murakami K, Murakami T, Onoda T, Sugi K, Takeyama H, Eda R. Simultaneous measurement of T-helper 1 cytokines in tuberculous pleural effusion. Int J Tuberc Lung Dis 2003; 7:1172-7. [PMID: 14677892] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/27/2023] Open
Abstract
OBJECTIVE Tuberculosis, the leading cause of death among infectious diseases worldwide, is a major cause of lymphocytic exudative pleural effusion. T-helper 1 cytokines, including interferon-gamma (IFN-gamma), interleukin (IL)-12p40 and IL-18 are predominantly associated with cell-mediated immune responses, and play an important role in immunity to Mycobacterium tuberculosis. DESIGN We studied 55 patients presenting with pleural effusion at the National Sanyo Hospital between April 2000 and September 2001 (42 men and 13 women; mean age 67 years). Twenty patients (36%) had tuberculous pleurisy, while 18 (33%) had malignant effusions and 17 (31%) had an effusion with another aetiology. Pleural fluid concentrations of IL-12p40 and IL-18 as well as IFN-gamma measured by enzyme-immunoassays. RESULTS Concentrations of all three cytokines were significantly higher in tuberculous than other pleural effusions. Significant correlations were evident between IFN-gamma and IL-12. We found particularly high concentrations of IL-12p40 and IFN-gamma in tuberculous patients with high fever. CONCLUSION The results indicate that T-helper 1 cytokines are involved in intrapulmonary cellular immune responses to M. tuberculosis, and suggest that the interactions between them may play an important role in the pathogenesis and severity of the pleural effusion. Understanding the development of this response may enhance our understanding of the pathogenesis of tuberculous pleural effusion and suggest new therapies.
Collapse
Affiliation(s)
- A Hiraki
- Department of Respiratory Medicine, Respiratory Disease Center, National Sanyo Hospital, Ube, Yamaguchi, Japan.
| | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Kunichika N, Murakami K, Makihata K, Takao K, Chikamori K, Aoe K, Miyahara N, Maeda T, Eda R, Takeyama H. [Orchiectomy for tuberculous epididymitis: a report of two cases with intractable to antituberculosis treatment]. Kekkaku 2001; 76:673-6. [PMID: 11712389] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/17/2023]
Abstract
This paper describes two cases with tuberculous epididymitis. The first case was a 69-year-old man who was admitted to our hospital because of ulceration or right scrotum. Physical examination revealed a hard, rounded, a little bigger than egg-sized mass in the right scrotum. The second case was a 40-year-old man who was admitted to our hospital because of cough, fever and body weight loss. He was treated for pulmonary tuberculosis with isoniazid, rifampicin, streptomycin and pyrazinamide. Six months after admission, he complained of a painless swelling of the right scrotum. Physical examination revealed a hard, rounded, more than egg-sized mass in the right scrotum. Right orchiectomy was performed in these two cases, and they were cured.
Collapse
Affiliation(s)
- N Kunichika
- Department of Internal Medicine, National Sanyo Hospital, 685, Higashi-Kiwa, Ube-shi, Yamaguchi 755-0241, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Miyahara N, Eda R, Umemori Y, Murakami T, Kunichika N, Makihata K, Aoe K, Murakami K, Takeyama H, Harada M. Pulmonary lymphoma of large B-cell type mimicking Wegener's granulomatosis. Intern Med 2001; 40:786-90. [PMID: 11518126 DOI: 10.2169/internalmedicine.40.786] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
A 27-year-old man with a primary pulmonary lymphoma of large B-cell type is described. Symptoms involved both the upper and lower respiratory tract. A chest roentgenogram showed a dense mass with cavitation. Transbronchial biopsy specimens revealed no atypical cells, rather they demonstrated granulomatous infiltration and vasculitis consistent with but not conclusively diagnostic of Wegener's granulomatosis. The pulmonary mass became smaller after sulfamethoxazole-trimethoprim therapy. These features suggested Wegener's granulomatosis. However, an open biopsy specimen was diagnostic for diffuse lymphoma of large B-cell type. High-grade pulmonary lymphoma should be considered in the differential diagnosis of patients with clinical and pathologic features suggesting Wegener's granulomatosis.
Collapse
Affiliation(s)
- N Miyahara
- Second Department of Medicine, Okayama University Medical School
| | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Miyahara N, Eda R, Takeyama H, Kunichika N, Moriyama M, Aoe K, Kohara H, Chikamori K, Maeda T, Harada M. Effects of short-term pulmonary rehabilitation on exercise capacity and quality of life in patients with chronic obstructive pulmonary disease. Acta Med Okayama 2000; 54:179-84. [PMID: 10985178 DOI: 10.18926/amo/32272] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Although the rehabilitation of patients with chronic obstructive pulmonary disease (COPD) improves both exercise capacity and quality of life, a standard protocol for COPD patients has not been established. To clarify whether physiologic and quality-of-life improvements can be achieved by an inpatient pulmonary rehabilitation program 5 days per week for 3 weeks, 18 patients with COPD were enrolled in a rehabilitation program. The physical exercise training regimen consisted of respiratory muscle stretch gymnastics and cycle ergometer exercise training. Pulmonary function tests, an incremental ergometer exercise test, a 6-min walking test, and a quality of life assessment by the Chronic Respiratory Questionnaire were administered before and after the program. The peak VO2, an indicator of maximal exercise capacity, did not increase, although the 6-min walking distance, an indicator of functional exercise capacity, increased significantly after rehabilitation. There was a significant improvement in the quality of life in terms of dyspnea, fatigue, and emotional state. These findings suggest that even a 3-week program may be beneficial for COPD patients. Increases in functional exercise capacity, even without an increase in maximal exercise capacity, are helpful for reducing dyspnea and improving quality of life parameters in patients with COPD.
Collapse
Affiliation(s)
- N Miyahara
- Department of Internal Medicine, Respiratory Disease Center, National Sanyo Hospital, Yamaguchi, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Umemori Y, Kotani K, Makihara S, Aoe K. [A case report of a mediastinal bronchogenic cyst with back pain]. Kyobu Geka 2000; 53:236-8. [PMID: 10714115] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/15/2023]
Abstract
We performed thoracoscopic surgery for a mediastinal bronchogenic cyst with complaining of back pain. The patient, a 38-year-old male, was admitted with an abnormal shadow on chest X-ray. Chest CT showed a localized tumor on the mediastine. MRI showed a cyst. Under thoracoscopy the tumor was based on parietal pleura and movable in chest cavity. We concluded that back pain was caused by a stimulus of a nerve in parietal pleura. Pathological diagnosis was a bronchogenic cyst.
Collapse
Affiliation(s)
- Y Umemori
- Department of Surgery, Sanyo National Hospital, Ube, Japan
| | | | | | | |
Collapse
|
31
|
Miyahara N, Eda R, Takeyama H, Maeda T, Aoe K, Kunichika N, Kohara H, Harada M. Cardiorespiratory responses during cycle ergometer exercise with different ramp slope increments in patients with chronic obstructive pulmonary disease. Intern Med 2000; 39:15-9. [PMID: 10674842 DOI: 10.2169/internalmedicine.39.15] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
OBJECTIVE The ramp exercise test has been widely used to evaluate cardiopulmonary responses to an incremental exercise load. This study was performed to clarify whether different slopes of the ramp exercise test influence exercise tolerance, exercise limiting factors, and respiratory pattern in patients with chronic obstructive pulmonary disease (COPD). SUBJECTS AND METHODS We applied three different slopes (5 W/min, 10 W/min and 20 W/min) of the ramp exercise test in 9 patients with COPD and evaluated cardiopulmonary responses. RESULTS There were no significant differences in peak oxygen uptake, anaerobic threshold (AT), minute ventilation, heart rate, arterial oxygen saturation, expired tidal volume, or respiratory rate at the maximal load among the three different ramp exercises tested. AT could be determined in six of nine patients (67%) at the slope of 5 W/min, in 8/9 (89%) at the slope of 10 W/min, and in 9/9 (100%) at the slope of 20 W/min. CONCLUSION The findings suggest that the ramp slope does not affect exercise tolerance, exercise limiting factors, or respiratory patterns and each of these ramp slopes is useful for the evaluation of COPD. Ramp slopes of 10 W/ min or 20 W/min should be appropriate for the determination of AT.
Collapse
Affiliation(s)
- N Miyahara
- Department of Internal Medicine, Respiratory Disease Center, National Sanyo Hospital, Ube, Yamaguchi
| | | | | | | | | | | | | | | |
Collapse
|
32
|
Abstract
We report the transient spontaneous disappearance of a mucocele due to bronchial atresia. Two years before presentation, a chest radiograph showed a hyperlucent right upper lung and a mucocele near the right hilum. A chest radiograph taken 1 year later showed that the mucocele had disappeared leaving an ovoid outline of a dilated bronchus. A chest radiograph obtained 3 months before presentation showed that the mucocele was present again. Atresia of the B3b bronchus of the right upper lobe was noted on thoracotomy. The "disappearance" of the mucocele probably was due to the clearance of mucoid material through collateral airways.
Collapse
Affiliation(s)
- N Miyahara
- Department of Internal Medicine, Respiratory Disease Center, National Sanyo Hospital, Ube, Yamaguchi
| | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Ikubo S, Takigawa N, Ueoka H, Kiura K, Tabata M, Shibayama T, Chikamori M, Aoe K, Matsushita A, Harada M. In vitro evaluation of antimicrotubule agents in human small-cell lung cancer cell lines. Anticancer Res 1999; 19:3985-8. [PMID: 10628341] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/15/2023]
Abstract
BACKGROUND The improvement of treatment outcome of small-cell lung cancer (SCLC), and search for new effective drugs and to overcome drug-resistance are essential. MATERIALS AND METHODS We evaluated the cytotoxicity of antimicrotubule agents to seven human SCLC cell lines consisting of one cell line (SBC-3) established from a previously untreated patient as a representative of drug-sensitive cell line, three cell lines (SBC-2, SBC-4, and -7) derived from treated patients as representatives of intrinsic drug-resistance cell lines, and three drug-resistant sublines (SBC-3/ADM, SBC-3/ETP, and SBC-3/CDDP) selected by continuous exposure of the SBC-3 cell line to increasing concentrations of doxorubicin, etoposide, or cisplatin as representatives of acquired drug-resistant cell lines. RESULTS IC50 values for SBC-2, -3, -4, and -7 cells of antimicrotubule agents were markedly lower than those of doxorubicin, etoposide, and cisplatin. Both SBC-3/ADM and SBC-3/ETP subline were highly resistant to paclitaxel, docetaxel, vinorelbine, vincristine, vindesine, and vinblastine. However, an SBC-3/ADM subline was not fully cross-resistant to rhizoxin, and an SBC-3/ETP subline was as sensitive to rhizoxin as an SBC-3 cell line. A cisplatin-resistant subline, SBC-3/CDDP, showed no cross-resistance to the antimicrotubule agents. CONCLUSION These results suggest that antimicrotubule agents are useful for SCLC, and rhizoxin may be particularly effective in the salvage treatment of refractory or relapsed patients.
Collapse
Affiliation(s)
- S Ikubo
- Second Department of Internal Medicine, Okayama University Medical School, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Matsushita A, Tabata M, Ueoka H, Kiura K, Shibayama T, Aoe K, Kohara H, Harada M. Establishment of a drug sensitivity panel using human lung cancer cell lines. Acta Med Okayama 1999; 53:67-75. [PMID: 10358721 DOI: 10.18926/amo/31626] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
We established a drug sensitivity panel consisting of 24 human lung cancer cell lines. Using this panel, we evaluated 26 anti-cancer agents: three alkylators, three platinum compounds, four antimetabolites, one topoisomerase I inhibitor, five topoisomerase II inhibitors, seven antimitotic agents and three tyrosine kinase inhibitors. This panel showed the following: a) Drug sensitivity patterns reflected their clinically-established patterns of action. For example, doxorubicin and etoposide were shown to be active against small cell lung cancer cell lines and mitomycin-C and 5-fluorouracil were active against non-small cell lung cancer cell lines, in agreement with clinical data. b) Correlation analysis of the mean graphs derived from the logarithm of IC50 values of the drugs gave insight into the mechanism of each drug's action. Thus, two drug combinations with reverse or no correlation, such as the combination of cisplatin and vinorelbine, might be good candidates for the ideal two drug combination in the treatment of lung cancer, as is being confirmed in clinical trials. c) Using cluster analysis of the cell lines in the panel with their drug sensitivity patterns, we could classify the cell lines into four groups depending on the drug sensitivity similarity. This classification will be useful to elucidate the cellular mechanism of action and drug resistance. Thus, our drug sensitivity panel will be helpful to explore new drugs or to develop a new combination of anti-cancer agents for the treatment of lung cancer.
Collapse
Affiliation(s)
- A Matsushita
- Second Department of Internal Medicine, Okayama University Medical School, Japan
| | | | | | | | | | | | | | | |
Collapse
|
35
|
Aoe K, Kiura K, Ueoka H, Tabata M, Matsumura T, Chikamori M, Matsushita A, Kohara H, Harada M. Effect of docetaxel with cisplatin or vinorelbine on lung cancer cell lines. Anticancer Res 1999; 19:291-9. [PMID: 10226557] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
Abstract
Docetaxel shows substantial activity against lung cancer. To find the optimal drug combination for docetaxel, we evaluated the effects of cisplatin, etoposide, mitomycin C, irinotecan, vindesine, and vinorelbine using three human lung cancer cell lines, ABC-1, EBC-1, and SBC-3. Drug cytotoxicity was determined by MTT assay. Tumor cells were incubated for 96 hours in the presence of docetaxel and each of the test drugs stated above. The combined drug interaction was evaluated by median-effect plot analysis and improved IC50-isobologram analysis. Both methods showed strong antagonism (subadditive or protective effect) between docetaxel and etoposide when tested on ABC-1 and EBC-1 cells. Docetaxel and cisplatin displayed additive effects on all cell lines tested, when evaluated by improved IC50-isobologram analysis. The combination of docetaxel and vinorelbine exerted synergistic effect on the growth inhibition of SBC-3 cells, which showed a wide range of fractional cytotoxicity when analyzed by median-effect plot and supraadditive when analyzed by improved IC50-isobologram. These observations suggest a possibility that docetaxel can be used in combination with vinorelbine or cisplatin in the treatment of lung cancer.
Collapse
Affiliation(s)
- K Aoe
- Second Department of Medicine, Okayama University Medical School, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Umemori Y, Makihara S, Fukuhara T, Nakashima K, Aoe K. [A resected case of a bronchiolo-alveolar cell carcinoma of the lung accompanying pneumonia-like shadow on chest roentgenogram]. Kyobu Geka 1998; 51:888-91. [PMID: 9757649] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
A 67-year-old female was admitted to our hospital because of pneumonia-like shadow on chest roentgenogram with persistent cough and sputum of 4 months duration. Diagnosis as lung cancer was delayed more than 4 months. She showed fever and inflammatory reactions. Antibiotics were effective to inflammatory reactions, but not effective to pneumonia-like shadow. Transbronchial lung biopsy was useful for the diagnosis. Right lower lobectomy was performed. In this case, tumor extents were limited within one lobe. Tumor cells did not invade blood and lymphatic vessels, and extrathoracic metastases were not detected. The prognosis of bronchiolo-alveolar cell carcinoma was determined by intra-pulmonary tumor extent. Based on a comparison with the outcome of unresected cases, bronchiolo-alveolar cell carcinoma limited within one lobe should be surgically resected.
Collapse
Affiliation(s)
- Y Umemori
- Department of Thoracic Surgery, National Sanyo Hospital, Yamaguchi, Japan
| | | | | | | | | |
Collapse
|
37
|
Kiura K, Watarai S, Ueoka H, Tabata M, Gemba K, Aoe K, Yamane H, Yasuda T, Harada M. An alteration of ganglioside composition in cisplatin-resistant lung cancer cell line. Anticancer Res 1998; 18:2957-60. [PMID: 9713491] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Previously we established cell lines resistant to Adriamycin and cisplatin to elucidate the mechanisms involved in acquired drug-resistance. In this study, we investigated ganglioside composition in drug-resistant cell lines. The Adriamycin-resistant cell line, SBC-3/ADM100, exhibited a ganglioside composition ratio similar to that of the parent SBC-3 cells. Densitometric analysis by resorcinol showed a 1.61-fold increase of ganglioside GM2 in SBC-3/ADM100 cells, when compared to the parent SBC-3 cells. The cisplatin-resistant cell line, SBC-3/CDDP, showed a simplified ganglioside pattern, expressing only gangliosides GM3 and GM2. SBC-3/CDDP cells showed a marked increase in ganglioside GM3. These findings suggest that the alteration of ganglioside composition may be actively involved in the acquisition of drug-resistance.
Collapse
Affiliation(s)
- K Kiura
- Second Department of Medicine, Okayama University Medical School, Japan.
| | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Ohke M, Yamadori I, Yuzurio S, Aoe K, Ozaki S, Kimura K, Yonei T, Kishimoto T. [A case of lung cancer with pericardial effusion without cardiac tamponade]. Nihon Kokyuki Gakkai Zasshi 1998; 36:77-80. [PMID: 9611981] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Cardiac tamponade as an initial manifestation of primary lung cancer is uncommon. All such cases had shown symptoms of cardiac tamponade at the first visit of the hospital. We report a case of lung cancer with pericardial effusion without cardiac tamponade. Echocardiography, revealed little pericardial effusion and it has not increased for 3 months. Pericardiotomy revealed adenocarcinoma and lung cancer was confirmed by bronchial biopsy. It is necessary to further examine patients with even slight amounts of pericardial effusion.
Collapse
Affiliation(s)
- M Ohke
- Department of Internal Medicine, Okayama Rousai Hospital, Japan
| | | | | | | | | | | | | | | |
Collapse
|
39
|
Kishimoto T, Okahara M, Chikamori K, Ozaki S, Aoe K, Ohke M, Fujioka H, Kimura K, Yonei T. [Clinical evaluation of benign asbestos pleurisy]. Nihon Kokyuki Gakkai Zasshi 1998; 36:18-22. [PMID: 9611971] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Seventeen cases of benign asbestos pleurisy were evaluated clinically. All cases were male and almost all cases were more than 60 years-old. Most cases presented with chief complaints of chest pain and dyspnea, but 2 cases had no complaints. Pleural effusion appeared predominantly in the right side. Six cases had 2 or 3 episodes of pleural effusion, and 1 case had 5. Ten cases had an occupational history of asbestos exposure in shipyards and 5 other cases had a history in building construction. Almost all cases had more than 30 years of exposure to asbestos and benign asbestos pleurisy appeared after more than 30 years from the first exposure to asbestos. Among the patients, 6 cases had diffuse pleural thickening and 2 cases had malignancies. Pleural fluid was bloody in 14 of 17 cases (82%) and all pleural fluid showed an exudate. Lymphocytes represented 70% and eosinophils 15% of the cellular population of the pleural fluid. Hyaluronic acid in pleural fluid in cases of benign asbestos pleurisy averaged 29.5 micrograms/ml, which was significantly (p < 0.05) lower than in malignant pleural mesothelioma. Leukocytosis in peripheral blood and a high CRP value were uncommon in benign asbestos pleurisy.
Collapse
Affiliation(s)
- T Kishimoto
- Department of Internal Medicine, Okayama Rousai Hospital, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Fujii M, Motoi M, Saeki H, Aoe K, Moriwaki S. Prognostic significance of proliferating cell nuclear antigen (PCNA) expression in non-small cell lung cancer. Acta Med Okayama 1993; 47:103-8. [PMID: 8099466 DOI: 10.18926/amo/31567] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Formalin-fixed, paraffin-embedded tissue sections of resected tumors from 90 patients were immunohistochemically studied to assess the prognostic value of proliferating cell nuclear antigen (PCNA) expression in non-small cell lung cancer. The individual tumors were classified into groups of high, moderate or low proliferative grade, and 38 (42.2%) patients had a high grade of proliferation. No statistically significant correlations were observed between PCNA grade and TNM status, pathological stage, resectability, histological type, degree of histological differentiation. Only vascular invasion significantly correlated with proliferative grade (p < 0.05). Survival analysis showed that patients with low proliferative grade tumors survived significantly longer (a 5-year survival rate of 83.3%) than those with high proliferative grade tumors (39.4%, p < 0.005). Cox's multivariate analysis revealed that PCNA grade was a significant prognostic determinant of survival. These results suggest that PCNA expression provides an independent prognostic variable for patients with non-small cell lung cancer and that it may be useful to consider this factor in treatment planning.
Collapse
Affiliation(s)
- M Fujii
- Department of Medicine, Shikoku Cancer Center Hospital, Ehime, Japan
| | | | | | | | | |
Collapse
|
41
|
Tanaka T, Inoue H, Date T, Okamura K, Aoe K, Takeda M, Kugita H, Murata S, Yamaguchi T, Kikkawa K. Synthesis of the optically active trans-isomers of diltiazem and their cardiovascular effects and Ca-antagonistic activity. Chem Pharm Bull (Tokyo) 1992; 40:1476-80. [PMID: 1394665 DOI: 10.1248/cpb.40.1476] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Optically active trans-isomers of diltiazem were synthesized and their cardiovascular effects were evaluated in anesthetized dogs and in isolated guinea pig hearts. Both (+)-2 (2R,3S) and (-)-2 (2S,3R) were much less active than diltiazem (1, 2S,3S) with short duration of action. No substantial enantiomeric difference in activity was seen between them. Their Ca-antagonistic activities on Ca(2+)-induced contractions in K(+)-depolarized canine basilar arteries were also examined. Absolute stereochemistry of (+)-2 was determined to be 2R,3S by X-ray crystallographic analysis.
Collapse
Affiliation(s)
- T Tanaka
- Organic Chemistry Research Laboratory, Tanabe Seiyaku Co., Ltd., Saitama, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Inoue H, Konda M, Hashiyama T, Otsuka H, Takahashi K, Gaino M, Date T, Aoe K, Takeda M, Murata S. Synthesis of halogen-substituted 1,5-benzothiazepine derivatives and their vasodilating and hypotensive activities. J Med Chem 1991; 34:675-87. [PMID: 1995892 DOI: 10.1021/jm00106a032] [Citation(s) in RCA: 55] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
In an attempt to improve the effectiveness and duration of the action of diltiazem (1), a 1,5-benzothiazepine calcium channel blocker, its derivatives (2) with halogen substituents on the fused benzene ring were synthesized. These compounds were evaluated for their effects on vertebral and coronary blood flows and antihypertensive activity. The structure-activity relationships are discussed. The 8-chloro derivative ((+)-2b), the most potent compound in this series, was selected for clinical evaluation as a cerebral vasodilating and antihypertensive agent.
Collapse
Affiliation(s)
- H Inoue
- Organic Chemistry Research Laboratory, Tanabe Seiyaku Co. Ltd., Saitama, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Nate H, Sekine Y, Oda K, Aoe K, Nakai H, Wada H, Takeda M, Yabana H, Nagao T. Synthesis of 2-phenylthiazolidine derivatives as cardiotonic agents. V. Modification of the thiazolidine moiety of 2-(phenylpiperazinylalkoxyphenyl)thiazolidine-3-thiocarboxami des and the corresponding carboxamides. Chem Pharm Bull (Tokyo) 1987; 35:3253-61. [PMID: 3427708 DOI: 10.1248/cpb.35.3253] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
|
44
|
Nate H, Sekine Y, Oda K, Aoe K, Nakai H, Wada H, Takeda M, Kotera K, Yabana H, Nagao T. Synthesis of 2-phenylthiazolidine derivatives as cardiotonic agents. III. Optically active isomers of N-methyl-2-(2-(2-(4-phenylpiperazino)ethoxy)phenyl)thiazolidine -3-carboxamides. Chem Pharm Bull (Tokyo) 1987; 35:2412-8. [PMID: 3664838 DOI: 10.1248/cpb.35.2412] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
|
45
|
Kodato S, Wada H, Saito S, Takeda M, Nishibata Y, Aoe K, Date T, Onoda Y, Tamaki H. Synthesis of novel pyridotriazepinones as antisecretory agents. Chem Pharm Bull (Tokyo) 1987; 35:80-9. [PMID: 3594670 DOI: 10.1248/cpb.35.80] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
|
46
|
Ikezaki M, Umino N, Gaino M, Aoe K, Iwakuma T, Oh-ishi T. [The synthesis and absolute stereochemistry of(-)-R-1-(4-Hydroxyphenyl)-2-[(3,4-dimethoxyphenethyl)amino]ethanol (denopamine)]. YAKUGAKU ZASSHI 1986; 106:80-9. [PMID: 3701602] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
|
47
|
Irie K, Aoe K, Tanaka T, Saito S. Stereoselective nucleophilic substitution of 6-methoxy-1-methoxycarbonylpipecolate: enantioselective synthesis of (+)-sedamine from L-lysine. ACTA ACUST UNITED AC 1985. [DOI: 10.1039/c39850000633] [Citation(s) in RCA: 39] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
48
|
Ban Y, Irie K, Okita M, Wakamatsu T, Nishibata Y, Aoe K, Kodera K. Regio- and Stereo-selective Synthesis of Amido-lactones by Anodic Oxidation. The Application for the Synthesis of Eburnamonine and Vincamine. HETEROCYCLES 1984. [DOI: 10.3987/s-1984-02-0689] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
49
|
Yamada K, Takeda M, Itoh N, Umino N, Ikezawa K, Kiyomoto A, Aoe K, Kotera K, Iwakuma T. Studies on 1,2,3,4-tetrahydroisoquinolines. IV. beta-Adrenoceptor activity and absolute stereochemistry of (-)-5,7-dihydroxy-1-(3,4,5-trimethoxybenzyl)-1,2,3,4-tetrahydroisoquinoline. Chem Pharm Bull (Tokyo) 1982; 30:1588-93. [PMID: 6288275 DOI: 10.1248/cpb.30.1588] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
|
50
|
Date T, Aoe K, Ohba M, Fujii T. [Lactams, XVI. X-ray molecular structure of 1-benzyl-5-ethyl-1,2,5,6-tetrahydro-2-oxo-4-pyridineacetic acid (author's transl)]. YAKUGAKU ZASSHI 1979; 99:865-9. [PMID: 541780 DOI: 10.1248/yakushi1947.99.8_865] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
|